ArticleCurrent oncology (Toronto, Ont.)2017
Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study.
Article in Current oncology (Toronto, Ont.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis.Scientific reports · 2020Pooled it
- Elderly Glioblastoma: Long-Course Versus Short-Course Chemoradiotherapy: A Regional New Zealand Retrospective Review.Journal of medical imaging and radiation oncology · 2026Article
- Impact of radiation fractionation on pseudoprogression in older patients with glioblastoma: a retrospective cohort study.CNS oncology · 2025Article
- Baseline total brain volume predicts changes in quality of life and overall survival after cranial radiotherapy in older patients with glioblastoma: Results from the prospective BRITER study.Neuro-oncology practice · 2024Article
- Treatment of very elderly glioblastoma patients ≥ 75 years of age: whom to treat.Journal of neuro-oncology · 2023Article
- Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma.Heliyon · 2023Article
- Molecular Pathways Implicated in Radioresistance of Glioblastoma Multiforme: What Is the Role of Extracellular Vesicles?International journal of molecular sciences · 2023Review
- Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma.Cancers · 2022Article
- Do elderly patients (≥ 75 years old) with glioblastoma benefit from more radical surgeries in the era of temozolomide?Neurosurgical review · 2022Article
- Treatment of Older Adult Patients with Glioblastoma: Moving towards the Inclusion of a Comprehensive Geriatric Assessment for Guiding Management.Current oncology (Toronto, Ont.) · 2022Review
- Is there a limited value of cytoreductive surgery in elderly patients with malignant gliomas?Surgical neurology international · 2022Article
- Baseline Serum C-Reactive Protein and Plasma Fibrinogen-Based Score in the Prediction of Survival in Glioblastoma.Frontiers in oncology · 2021Article
- Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.Journal of cancer research and clinical oncology · 2021Article
- ＜Editors' Choice＞ Impact of maintenance of postoperative performance status on survival in elderly patients over 70 with high-grade astrocytoma.Nagoya journal of medical science · 2020Article
- Glioblastomas located in proximity to the subventricular zone (SVZ) exhibited enrichment of gene expression profiles associated with the cancer stem cell state.Journal of neuro-oncology · 2020Article
- An audit of the management of elderly patients with glioblastoma in the UK: have recent trial results changed treatment?CNS oncology · 2019Article
- SB365,Molecules (Basel, Switzerland) · 2019Article
- Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study.CNS oncology · 2019Article
- Characteristics of treatment and outcome in elderly patients with brain glioblastoma: a retrospective analysis of case series.Acta clinica Croatica · 2019Article
- A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer.Journal of translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeElderly patients make up a large percentage of the individuals newly diagnosed with glioblastoma (gbm), but they face particular challenges in tolerating standard therapy, and compared with younger patients, they experience significantly shorter survival. We set out to compare clinical characteristics, treatment patterns, and outcomes in a non-elderly group (<65 years) and an elderly group (≥65 years) of patients diagnosed with gbm.
methodsThis retrospective population-based study used a province-wide cancer registry to identify patients with a new diagnosis of gbm within a 6-year period (2006-2012). Of the 138 patients identified, 56 (40.6%) were 65 years of age or older. Demographic characteristics, treatment patterns, and overall survival (os) in the elderly and non-elderly groups were compared. Predictors of os were determined using multivariate analysis.
resultsElderly patients were more likely to present with a poor performance status (Eastern Cooperative Oncology Group ≥ 2), to undergo biopsy without resection, and to receive whole-brain or hypofractionated radiotherapy. Compared with non-elderly patients, the elderly patients were less likely to receive adjuvant temozolomide. Survival time was significantly shorter in the elderly than in the non-elderly patients (7.2 months vs. 11.2 months). In multivariate analysis, surgical resection, hypofractionated radiotherapy (compared with whole-brain or conventional radiotherapy), and chemotherapy were predictive of os in older patients. Among elderly patients receiving radiation, survival was improved with the use of combined therapy compared with the use of radiation only (11.3 months vs. 4.6 months).
conclusionsOverall survival was shorter for elderly patients with gbm than for non-elderly patients; the elderly patients were also less likely to receive intensive surgical or adjuvant therapy. Our population-based analysis demonstrated improved os with surgical resection, hypofractionated radiotherapy, and temozolomide, and supports the results of recent clinical trials demonstrating a benefit for combination chemoradiotherapy in older patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.